Major Pharma Short Sellers Hike Their Bets

Print Email

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.

The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It is yet to be seen how much headway it can actually make with these reforms.

Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.

Short interest in Pfizer Inc. (NYSE: PFE) increased to 50.35 million shares from the previous 49.88 million. The stock was last seen trading at $42.48, within a 52-week range of $33.20 to $45.81.

The number of Merck & Co. Inc. (NYSE: MRK) shares short fell slightly to 17.35 million from 17.40 million in the previous period. Its shares were trading at $70.54, in a 52-week range of $52.83 to $73.49.

Bristol-Myers Squibb Co. (NYSE: BMY) short interest dropped to 12.93 million shares from the previous reading of 13.50 million. Shares were last seen at $48.83, in a 52-week trading range of $48.67 to $70.05.

The number of shares short in AbbVie Inc. (NYSE: ABBV) increased to 32.65 million from the previous 31.01 million. The stock was trading at $79.41, and its 52-week range is $79.26 to $125.86.

Eli Lilly and Co.’s (NYSE: LLY) short interest rose to 15.22 million shares from the previous 9.45 million. The stock was trading at $106.32. The 52-week range is $73.69 to $116.61.

Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest increased to 32.61 million from the previous level of 31.80 million. Shares were trading at $19.81, in a 52-week range of $10.85 to $25.96.